基于的方法直接针对帕金森病中的α-synuclein
Scott G Allen1, Richard M Meade1, Lucy L White Stenner1
1Department of Life Sciences, University of Bath, Claverton Down, Bath, BA2 7AY, UK.
Molecular neurodegeneration
|November 8, 2023
概括
可以通过向α-synuclein聚合来治疗帕金森病. 这些分子旨在防止神经元中有毒蛋白质的积累,在当前治疗方法失败的地方提供希望.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 阿尔法同核素错误折叠和聚合是帕金森病 (PD) 和相关的同核素病变的核心原因.
- 形成有毒的细胞内利维体,主要由α-synuclein组成,是PD的标志.
- 目前的治疗策略缺乏预防或减缓PD进展的选择.
研究的目的:
- 审查和总结开发和模拟剂以向α-synuclein的努力.
- 探索这些分子在调节α-synuclein聚合和毒性的潜力.
- 突出的承诺作为治疗或早期生物标志物用于synucleinopathies.
主要方法:
- 对针对同核蛋白病变的基于的治疗方法的当前文献的综述.
- 分析可以通过血脑屏障进入神经元的策略.
- 评估与α-synuclein的接触,以抑制聚合和毒性.
主要成果:
- 和它们的模拟物正在成为细胞内标的可行药物候选者.
- 开发重点是调节α-synuclein聚合和相关的神经毒性.
- 这些分子显示出治疗干预和早期疾病检测的潜力.
结论:
- 基于的治疗方法为治疗帕金森病和相关的同核蛋白病变提供了有前途的途径.
- 成功的发育需要可以穿透血脑屏障并准特定的神经元通路.
- 该领域在解决神经退行性疾病中未得到满足的医疗需求方面具有重大潜力.
相关概念视频
Parkinson's Disease: Treatment
281
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
281
Parkinson's Disease: Overview
564
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
564
Neural Regulation
39.5K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.5K
Alzheimer's Disease: Treatment
197
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
197


